pharmaceutical investing Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial
pharmaceutical investing Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin) in combination with KEYTRUDA (pembrolizumab) for Triple Negative Breast Cancer
Westport Announces Closing of US$10 Million Registered Direct Offering and Concurrent Private Placement
Tartisan Nickel Corp. Acquires Nickel-Copper Claims, Outlines 2026 Work Program at Turtle Pond, Northwestern Ontario
